Cardiff Metropolitan University has been instrumental in the development of a new anti-cancer agent that has the potential to offer a novel and valuable first in class treatment option for cancer.

Cardiff Metropolitan University reports the global IP, which relates to the anti-thrombotic agent anagrelide, was recently acquired by SUDA Ltd, a leader in oro-mucosal drug delivery, from Cardiff Metropolitan University’s partners, Aluztra Bio Ltd.

Anagrelide is a drug currently used for the treatment of essential thrombocytosis to reduce raised levels of platelets which, in addition to increasing the risk of blood clots, are a key factor in the metastasis of tumours. Scientists have identified that platelets nourish and protect cancer cells, enabling them to evade the immune system and spread through the body to form metastases. As a result, survival rates are lower in those patients with the highest platelet numbers.

Whilst the IP, developed in significant part here in Wales, has shown anagrelide’s promise as a novel anti-cancer agent, its use is currently limited by side effects to the heart. Australian-based SUDA believes it can overcome this potential problem by delivering the drug as a mouth spray using the company’s OroMist technology. This avoids the metabolism of the drug in the liver, where the side effect causing metabolite is generated.

The global market for cancer drugs has grown to more than $100bn in annual sales. Newer cancer treatments include immunotherapies that stimulate the patient’s own immune system. Anagrelide would be complementary to such treatments by reducing the platelet numbers and therefore reducing the protective effect that platelets exhibit on metastatic cells.

Professor of Biomedical Sciences, Jorge D Erusalimsky, who led the research at Cardiff Metropolitan University, said “The experimental work carried out within Cardiff Metropolitan University has unveiled the ability of anagrelide to subdue cancer cells in a test tube by blocking their stimulatory influence on the production of platelets from their precursors, showing the potential of our basic research to make a difference in the real world.”

Aluztra Bio, Cardiff Metropolitan University and their partners will be entitled to a low single digit percentage royalty on direct and indirect net sales generated by SUDA from commercialisation of its oro-mucosal spray of anagrelide.